Abstract | STUDY OBJECTIVE: DESIGN: Randomized, double-blind, placebo-controlled, multicenter trial. SETTING: Five lipid clinics with a central laboratory and coordinating center. PATIENTS: INTERVENTIONS: Patients were on a lipid-lowering diet throughout the study. After a 4-week placebo baseline period, patients were randomized to five equal treatment groups. Each group received a different sequence of placebo or lovastatin 5 to 40 mg twice daily or 20 to 40 mg once daily in the evening, during three consecutive 6-week periods. MEASUREMENTS AND MAIN RESULTS: CONCLUSION:
|
Authors | R J Havel, D B Hunninghake, D R Illingworth, R S Lees, E A Stein, J A Tobert, S R Bacon, J A Bolognese, P H Frost, G E Lamkin |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 107
Issue 5
Pg. 609-15
(Nov 1987)
ISSN: 0003-4819 [Print] United States |
PMID | 3662274
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Apolipoproteins B
- Cholesterol
- Lovastatin
- Alanine Transaminase
|
Topics |
- Adult
- Alanine Transaminase
(blood)
- Apolipoproteins B
(blood)
- Cataract
(chemically induced)
- Cholesterol
(blood)
- Double-Blind Method
- Drug Administration Schedule
- Drug Evaluation
- Female
- Heterozygote
- Humans
- Hyperlipoproteinemia Type II
(drug therapy, genetics)
- Lovastatin
(administration & dosage, adverse effects, therapeutic use)
- Male
- Random Allocation
|